FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W150314275> ?p ?o ?g. }

• W150314275 endingPage "965" @default.
• W150314275 startingPage "956" @default.
• W150314275 abstract "Although hematopoietic recovery following high-dose chemotherapy (HD-CT) and peripheral blood progenitor cell (PBPC) transplantation is rapid, there is still a 5- to 7-day period of severe neutropenia which, theoretically, might be abrogated by an additional transplantation of more differentiated myeloid post-progenitor cells (MPPC). However, both the number of MPPC required to abrogate neutropenia as well as the optimum scheduling of MPPC infusions are currently unknown. Therefore, these questions were addressed by applying a computer model of human granulopoiesis. First, model calculations simulating varying levels of chemotherapy dose intensity were performed and compared with typical clinical neutrophil recovery curves. Using this approach, the data for HD-CT without PBPC transplantation could be reproduced by assuming a reduction of stem cells, committed granulopoietic progenitors and proliferating precursors to about 0.001% of normal. PBPC-supported HD-CT was reproduced by increasing the starting values to at least 0.1%, which corresponded to about 1 to 2 x 10(5)/kg transplanted CFU-GM. Interestingly, reproduction of PBPC-supported HD-CT data could be observed for a wide range of starting values (0.1%-10% of normal), thus confirming the clinical observation that hematopoietic recovery after PBPCT cannot be improved by increasing the dose of transplanted cells over a certain threshold. Using the same simulation model, we then studied the effects of an additional MPPC transplantation. The results showed, that at least 5.7 X 10(8) MPPC/kg have to be provided in addition to the normal PBPC graft to avoid neutropenia <100/microL, and that MPPC are best transplanted on days 0 and 6 after HD-CT. Assuming a 100- to 120-fold cellular ex-vivo expansion rate and MPPC representing about 70% of total expanded cells, 5.7 X 10(8) MPPC/kg could be generated starting from 1 to 2 leukapheresis preparations with about 7 to 8 x 10(6) CD34+ PBPC/kg. Considering furthermore, that only a fraction of ex-vivo generated cells will seed and effectively produce neutrophils in-vivo, the required number of MPPC is most likely even higher and, therefore, might be difficult to be achieved clinically. However, the validity of the model results remains to be proven in appropriate clinical studies." @default.
• W150314275 created "2016-06-24" @default.
• W150314275 creator A5007903215 @default.
• W150314275 creator A5011836836 @default.
• W150314275 creator A5012524816 @default.
• W150314275 creator A5042780466 @default.
• W150314275 creator A5054985920 @default.
• W150314275 creator A5060761629 @default.
• W150314275 creator A5066624700 @default.
• W150314275 date "1999-05-01" @default.
• W150314275 modified "2023-10-14" @default.
• W150314275 title "How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after peripheral blood progenitor cell transplantation?" @default.
• W150314275 cites W160332237 @default.
• W150314275 cites W1870232274 @default.
• W150314275 cites W1923339639 @default.
• W150314275 cites W1975174081 @default.
• W150314275 cites W1976528127 @default.
• W150314275 cites W1999884087 @default.
• W150314275 cites W2008065345 @default.
• W150314275 cites W2016434172 @default.
• W150314275 cites W2020751729 @default.
• W150314275 cites W2021371613 @default.
• W150314275 cites W2040066514 @default.
• W150314275 cites W2043914813 @default.
• W150314275 cites W2059228557 @default.
• W150314275 cites W2066998689 @default.
• W150314275 cites W2086886868 @default.
• W150314275 cites W2111631533 @default.
• W150314275 cites W2128390662 @default.
• W150314275 cites W2132167316 @default.
• W150314275 cites W2139596805 @default.
• W150314275 cites W2298694094 @default.
• W150314275 cites W2299422460 @default.
• W150314275 cites W2309502478 @default.
• W150314275 cites W2339456987 @default.
• W150314275 cites W2404959529 @default.
• W150314275 cites W274009566 @default.
• W150314275 cites W4229510792 @default.
• W150314275 cites W4232587867 @default.
• W150314275 cites W4238068707 @default.
• W150314275 cites W4240984821 @default.
• W150314275 cites W4241334625 @default.
• W150314275 cites W58423710 @default.
• W150314275 doi "https://doi.org/10.1016/s0301-472x(99)00026-0" @default.
• W150314275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10340412" @default.
• W150314275 hasPublicationYear "1999" @default.
• W150314275 type Work @default.
• W150314275 sameAs 150314275 @default.
• W150314275 citedByCount "25" @default.
• W150314275 crossrefType "journal-article" @default.
• W150314275 hasAuthorship W150314275A5007903215 @default.
• W150314275 hasAuthorship W150314275A5011836836 @default.
• W150314275 hasAuthorship W150314275A5012524816 @default.
• W150314275 hasAuthorship W150314275A5042780466 @default.
• W150314275 hasAuthorship W150314275A5054985920 @default.
• W150314275 hasAuthorship W150314275A5060761629 @default.
• W150314275 hasAuthorship W150314275A5066624700 @default.
• W150314275 hasBestOaLocation W1503142751 @default.
• W150314275 hasConcept C109159458 @default.
• W150314275 hasConcept C126322002 @default.
• W150314275 hasConcept C201750760 @default.
• W150314275 hasConcept C203014093 @default.
• W150314275 hasConcept C2776694085 @default.
• W150314275 hasConcept C2777063308 @default.
• W150314275 hasConcept C2777408962 @default.
• W150314275 hasConcept C2779282312 @default.
• W150314275 hasConcept C2779452902 @default.
• W150314275 hasConcept C28328180 @default.
• W150314275 hasConcept C2911091166 @default.
• W150314275 hasConcept C502942594 @default.
• W150314275 hasConcept C71924100 @default.
• W150314275 hasConcept C86803240 @default.
• W150314275 hasConcept C95444343 @default.
• W150314275 hasConceptScore W150314275C109159458 @default.
• W150314275 hasConceptScore W150314275C126322002 @default.
• W150314275 hasConceptScore W150314275C201750760 @default.
• W150314275 hasConceptScore W150314275C203014093 @default.
• W150314275 hasConceptScore W150314275C2776694085 @default.
• W150314275 hasConceptScore W150314275C2777063308 @default.
• W150314275 hasConceptScore W150314275C2777408962 @default.
• W150314275 hasConceptScore W150314275C2779282312 @default.
• W150314275 hasConceptScore W150314275C2779452902 @default.
• W150314275 hasConceptScore W150314275C28328180 @default.
• W150314275 hasConceptScore W150314275C2911091166 @default.
• W150314275 hasConceptScore W150314275C502942594 @default.
• W150314275 hasConceptScore W150314275C71924100 @default.
• W150314275 hasConceptScore W150314275C86803240 @default.
• W150314275 hasConceptScore W150314275C95444343 @default.
• W150314275 hasIssue "5" @default.
• W150314275 hasLocation W1503142751 @default.
• W150314275 hasLocation W1503142752 @default.
• W150314275 hasOpenAccess W150314275 @default.
• W150314275 hasPrimaryLocation W1503142751 @default.
• W150314275 hasRelatedWork W1508224173 @default.
• W150314275 hasRelatedWork W1900518383 @default.
• W150314275 hasRelatedWork W199911731 @default.
• W150314275 hasRelatedWork W2014888993 @default.
• W150314275 hasRelatedWork W2080588166 @default.

• next